Skip to main content
    E

    Editas Medicine Inc (EDIT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.87
    -0.30 (-13.82%)

    Market Cap: $334.92M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Editas Medicine Inc (EDIT) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Editas Medicine are Precision BioSciences (DTIL), Prime Medicine, Inc. Common Stock (PRME) and PepGen (PEPG). By market cap, Editas Medicine ranks 9th of the 13 companies on this page; Prime Medicine, Inc. Common Stock (PRME) is the largest at $949.85M.

    Peer Comparison

    EDIT's ROIC of -42.3% is below the peer median of -23.4%, and its revenue growth of 37.4% is above the median of -44.2%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Editas Medicine (EDIT)$334.92MN/A5.6x-145.0%-42.3%37.4%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    Prime Medicine, Inc. Common Stock (PRME)$949.85MN/A105.5x0.0%N/A243.9%0.00%
    PepGen Ltd (PEPG)$410.98MN/AN/A0.0%N/A0.0%0.00%
    DiaMedica Therapeutics Inc (DMAC)$474.29MN/AN/A0.0%N/A0.0%0.00%
    CorMedix Inc (CRMD)$370.64M6.3x0.9x15.5%13.9%-47.7%0.00%
    Cartesian Therapeutics Inc. (RNAC)$193.69MN/A179.8x0.0%147.2%-92.9%0.00%
    Enanta Pharmaceuticals Inc (ENTA)$320.09MN/A4.8x-96.9%N/A-21.6%0.00%
    Korro Bio, Inc. (KRRO)$186.81MN/A175.8x0.0%-82.8%-43.1%0.00%
    Opus Genetics, Inc. (IRD)$384.68MN/A52.0x0.0%-145.1%-63.1%0.00%
    MiMedx Group Inc (MDXG)$468.42M106.0x1.5x-6.3%N/A-45.2%0.00%
    Regenxbio Inc (RGNX)$505.18MN/A3.1x-113.9%N/A-69.2%0.00%
    Entera Bio Ltd (ENTX)$541.57MN/AN/A0.0%-8.5%-100.0%0.00%
    Peer median$397.83M56.2x4.8x0.0%-23.4%-44.2%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Editas Medicine, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors
    Prime Medicine, Inc. Common Stock (PRME)
    Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology...
    PRME competitors
    PepGen Ltd (PEPG)
    PepGen Inc., a clinical-stage biotechnology company, is focused on the development of oligonucleotide therapeutics for use in the treatment of serious...
    PEPG competitors
    DiaMedica Therapeutics Inc (DMAC)
    DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, develops treatments for neurological and kidney diseases.
    DMAC competitors
    CorMedix Inc (CRMD)
    CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious...
    CRMD competitors
    Cartesian Therapeutics Inc. (RNAC)
    Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs...
    RNAC competitors
    Enanta Pharmaceuticals Inc (ENTA)
    Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.
    ENTA competitors
    Korro Bio, Inc. (KRRO)
    Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare...
    KRRO competitors
    Opus Genetics, Inc. (IRD)
    Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision.
    IRD competitors
    MiMedx Group Inc (MDXG)
    MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
    MDXG competitors
    Regenxbio Inc (RGNX)
    REGENXBIO Inc., a clinical-stage biotechnology company, offers candidate gene therapy products to deliver genes to cells to address genetic defects or to enable...
    RGNX competitors
    Entera Bio Ltd (ENTX)
    Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies...
    ENTX competitors

    Frequently Asked Questions About EDIT

    Who are Editas Medicine's main competitors?

    The companies most similar to Editas Medicine include Precision BioSciences (DTIL), Prime Medicine, Inc. Common Stock (PRME), PepGen (PEPG), DiaMedica Therapeutics (DMAC) and CorMedix (CRMD), listed from the closest match.

    Who is Editas Medicine's biggest competitor?

    Prime Medicine, Inc. Common Stock (PRME) is the largest of the similar companies at $949.85M; Precision BioSciences (DTIL) is the closest match by business profile, size, sector and industry.

    How does EDIT stock compare with its competitors?

    EDIT's P/S is 5.6x against a peer median of 4.8x; its net margin is -145.0% against a peer median of 0.0%.

    Which of Editas Medicine's competitors pays a higher dividend?

    Editas Medicine pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Editas Medicine bigger than its competitors?

    No. Editas Medicine is 9th by market cap among the 13 companies on this page; the largest is Prime Medicine, Inc. Common Stock (PRME) at $949.85M.